Led by Michael Ritchie, Corellia is a technology-enabled biotech developing first-in-class antibody drug conjugates for the treatment of solid and hematologic malignancies. Corellia launched out of Champions Oncology, Inc. in 2023, leveraging the world's deepest multi-omic dataset and living tumor bank for computationally driven target discovery. Leveraging this technology, Corellia has identified an extensive list of novel cell surface targets and is building a rich therapeutic pipeline.
